MedTrace Logo

A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines

NCT04586673 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-04-29

Study results available
· View outcomes & findings →

Summary

The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.

In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.tHIVconsv1, MV.tHIVconsv3 and MVA.tHIVconsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.

3 healthy, HIV-1 negative adult volunteers will receive one vaccination of low dose ChAdOx1.tHIVconsv1. A further 10 healthy, HIV-1 negative adult volunteers will receive a higher dose of ChAdOx1.tHIVconsv1, followed by one vaccination each of MVA.tHIVconsv3 and MVA.tHIVconsv4 4 weeks later.

Conditions

Interventions

BIOLOGICAL

ChAdOx1.tHIVconsv1 (C1)

ChAdOx1.tHIVconsv1 5 x 10\^9 vp

BIOLOGICAL

ChAdOx1.tHIVconsv1 (C1)

ChAdOx1.tHIVconsv1 5 x 10\^10 vp

BIOLOGICAL

MVA.tHIVconsv3 (M3)

MVA.tHIVconsv3 1 x 10\^8 pfu

BIOLOGICAL

MVA.tHIVconsv4 (M4)

MVA.tHIVconsv4 09. x 10\^8 pfu

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Paola Cicconi · Dr Paola Cicconi

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-03
Primary Completion
2022-08-03
Completion
2022-08-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04586673 on ClinicalTrials.gov